GlassScriptPhysician profile
James L Harper
NPI 1609820240
$16,534.13
in general payments reported to CMS, 2019-2025
11 companies · $15.97 in 2025
The $15.97 reported for 2025 was less than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,842 · 2021: $1,541 · 2022: $80.10 · 2023: $220 · 2024: $14.99 · 2025: $15.97.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $250.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $10,619.63 | 2019 | |
| Bioverativ Therapeutics INC. | $3,842.00 | 2020 | |
| Novo Nordisk INC | $1,530.00 | 2021 | |
| Genzyme Corporation | $153.39 | 2022-2023 | |
| Genentech USA, INC. | $148.54 | 2019-2024 | Hemlibra |
| Novartis Pharmaceuticals Corporation | $115.60 | 2019-2022 | |
| Pfizer INC. | $76.12 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.41 | 2023 | |
| Y-Mabs Therapeutics, INC. | $21.44 | 2023 | Danyelza |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.